§ 02 · Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇹🇭Thailand Fees verified 12 September 2026	🇺🇸United States Fees verified 12 September 2026
Authority & dossier
Fee confirmation	Fees verified 12 September 2026	Fees verified 12 September 2026
Regulatory authority	Thai FDA	FDA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	No	Yes
Reliance pathway	Available	None
Reference agencies	FDA (US), EMA, MHRA (UK), Health Canada +4	Not stated
Lead pathway (timeline & fees), New Drug Registration, Standard Review · New Drug Application, 505(b)(1)
Pathway name	New Drug Registration, Standard Review	New Drug Application, 505(b)(1)
Approval timeline	365-730 days	304-365 days
Headline fee and pathway	THB 114,500, New Drug Registration, Standard Review	USD 4,682,003, New Drug Application, 505(b)(1)conditional on other
Recurring charges	Certificate renewal applies, amount not published, every 7 years, per certificate	USD 442,213 a year, per product
Local representative	Required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	No
Local responsible person	Yes	Yes
RP role	Registration holders must designate a qualified pharmacist (registered with the Pharmacy Council of Thailand) as the responsible person for the licensed premises, and a contact for pharmacovigilance reporting.	US Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.
Accelerated pathways
Designations available	2 designations	6 designations
Examples	Public Health Emergency / Conditional Approval, Safety Monitoring Programme (SMP) Conditional Registration	Priority Review, Breakthrough Therapy Designation, Accelerated Approval, Subpart H/E +3
Post-approval lifecycle
Variations framework	Variations classified per Thai FDA guidelines into major (require approval, e.g., new indication, formulation change, new manufacturing site) and minor (notification). New indications follow the new-drug pathway with SMP.	FDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS), the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.
Renewal cycle	Drug registration is valid indefinitely for most products once unconditional, subject to ongoing pharmacovigilance and GMP compliance; controlled substances and biologicals follow specific renewal cycles.	FDA does not require periodic renewal of NDAs or BLAs, approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.
Pharmacovigilance	Thai FDA's Health Product Vigilance Centre (HPVC) coordinates national ADR reporting (Thailand is a member of the WHO Programme for International Drug Monitoring, Uppsala). Marketing authorisation holders must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances. The SMP provides additional intensive monitoring for the first 2 years.	Mandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Not permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60-120 days	30-30 days
GCP standard	ICH E6(R2) GCP; Thai FDA Good Clinical Practice Guidelines	ICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56
Pricing & reimbursement
Price regulation	Regulated	Free pricing
Reference pricing	Yes	No
HTA required	Yes	No
HTA body	Health Intervention and Technology Assessment Program (HITAP), supporting NLEM Subcommittee	ICER (Institute for Clinical and Economic Review), independent, non-binding

Verdict colours indicate lower, moderate, or higher regulatory burden, they're not value judgements on a market.

Authority & dossier

Fee confirmation

ThailandFees verified 12 September 2026
United StatesFees verified 12 September 2026

Regulatory authority

ThailandThai FDA
United StatesFDA

English submissions

ThailandYes
United StatesYes

CTD accepted

ThailandYes
United StatesYes

eCTD accepted

ThailandNo
United StatesYes

Reliance pathway

ThailandAvailable
United StatesNone

Reference agencies

ThailandFDA (US), EMA, MHRA (UK), Health Canada +4
United StatesNot stated

Lead pathway (timeline & fees), New Drug Registration, Standard Review · New Drug Application, 505(b)(1)

Pathway name

ThailandNew Drug Registration, Standard Review
United StatesNew Drug Application, 505(b)(1)

Approval timeline

Thailand365-730 days
United States304-365 days

Headline fee and pathway

ThailandTHB 114,500, New Drug Registration, Standard Review
United StatesUSD 4,682,003, New Drug Application, 505(b)(1)conditional on other

Recurring charges

ThailandCertificate renewal applies, amount not published, every 7 years, per certificate
United StatesUSD 442,213 a year, per product

Local representative

ThailandRequired
United StatesNot required

Local manufacturing

ThailandNot required
United StatesNot required

GMP inspection

ThailandRequired
United StatesRequired

MAH & local presence

Local entity required

ThailandYes
United StatesNo

Local responsible person

ThailandYes
United StatesYes

RP role

ThailandRegistration holders must designate a qualified pharmacist (registered with the Pharmacy Council of Thailand) as the responsible person for the licensed premises, and a contact for pharmacovigilance reporting.
United StatesUS Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.

Accelerated pathways

Designations available

Thailand2 designations
United States6 designations

Examples

ThailandPublic Health Emergency / Conditional Approval, Safety Monitoring Programme (SMP) Conditional Registration
United StatesPriority Review, Breakthrough Therapy Designation, Accelerated Approval, Subpart H/E +3

Post-approval lifecycle

Variations framework

ThailandVariations classified per Thai FDA guidelines into major (require approval, e.g., new indication, formulation change, new manufacturing site) and minor (notification). New indications follow the new-drug pathway with SMP.
United StatesFDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS), the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.

Renewal cycle

ThailandDrug registration is valid indefinitely for most products once unconditional, subject to ongoing pharmacovigilance and GMP compliance; controlled substances and biologicals follow specific renewal cycles.
United StatesFDA does not require periodic renewal of NDAs or BLAs, approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.

Pharmacovigilance

ThailandThai FDA's Health Product Vigilance Centre (HPVC) coordinates national ADR reporting (Thailand is a member of the WHO Programme for International Drug Monitoring, Uppsala). Marketing authorisation holders must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances. The SMP provides additional intensive monitoring for the first 2 years.
United StatesMandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.

Unlicensed access

Named Patient Supply

ThailandAvailable
United StatesAvailable

Compassionate Use

ThailandAvailable
United StatesAvailable

Emergency Import

ThailandAvailable
United StatesAvailable

Parallel Import

ThailandNot permitted
United StatesNot permitted

Clinical trials

CTA approval

ThailandRequired
United StatesRequired

Ethics approval

ThailandYes
United StatesYes

CTA timeline

Thailand60-120 days
United States30-30 days

GCP standard

ThailandICH E6(R2) GCP; Thai FDA Good Clinical Practice Guidelines
United StatesICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56

Pricing & reimbursement

Price regulation

ThailandRegulated
United StatesFree pricing

Reference pricing

ThailandYes
United StatesNo

HTA required

ThailandYes
United StatesNo

HTA body

ThailandHealth Intervention and Technology Assessment Program (HITAP), supporting NLEM Subcommittee
United StatesICER (Institute for Clinical and Economic Review), independent, non-binding